Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Hanefeld

Showing results (1-10 of 224) with videos related to

Pageof 23
Sort By:
Deutsche Medizinische Wochenschrift (1946)|April 3, 2008
[Controlled studies in German language publications]M Hanefeld
European Journal of Clinical Investigation|September 7, 2000
Postprandial state abnormalities: neglected cardiovascular risk factors in diabetes. IntroductionM Hanefeld
MMW Fortschritte Der Medizin|June 26, 2001
[The new oral antidiabetics. Type 2 diabetes under control only with tablets?]M Hanefeld
International Journal of Clinical Practice|August 15, 2001
Clinical rationale for rosuvastatin, a potent new HMG-CoA reductase inhibitorM Hanefeld
MMW Fortschritte Der Medizin|February 12, 2005
[Glucose-independent impact of the glitazones on the cardiovascular outcome]M Hanefeld
International Journal of Clinical Practice. Supplement|October 12, 2001
Pharmacokinetics and clinical efficacy of pioglitazoneM Hanefeld
International Journal of Clinical Practice. Supplement|November 7, 2000
Post-prandial hyperglycaemia and vascular diseaseM Hanefeld
Diabetes, Obesity & Metabolism|June 13, 2009
The role of pioglitazone in modifying the atherogenic lipoprotein profileM Hanefeld
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|March 6, 2003
STOP-NIDDM: a new paradigm for diabetes prevention?M Hanefeld
Zeitschrift Fur Arztliche Fortbildung|January 1, 1984
[Nutrition in hyperlipoproteinemias from the preventive and therapeutic viewpoint]M Hanefeld
Pageof 23

Showing results (1-10 of 224) with videos related to

Sort By:
Pageof 23
Deutsche Medizinische Wochenschrift (1946)|April 3, 2008
[Controlled studies in German language publications]M Hanefeld
European Journal of Clinical Investigation|September 7, 2000
Postprandial state abnormalities: neglected cardiovascular risk factors in diabetes. IntroductionM Hanefeld
MMW Fortschritte Der Medizin|June 26, 2001
[The new oral antidiabetics. Type 2 diabetes under control only with tablets?]M Hanefeld
International Journal of Clinical Practice|August 15, 2001
Clinical rationale for rosuvastatin, a potent new HMG-CoA reductase inhibitorM Hanefeld
MMW Fortschritte Der Medizin|February 12, 2005
[Glucose-independent impact of the glitazones on the cardiovascular outcome]M Hanefeld
International Journal of Clinical Practice. Supplement|October 12, 2001
Pharmacokinetics and clinical efficacy of pioglitazoneM Hanefeld
International Journal of Clinical Practice. Supplement|November 7, 2000
Post-prandial hyperglycaemia and vascular diseaseM Hanefeld
Diabetes, Obesity & Metabolism|June 13, 2009
The role of pioglitazone in modifying the atherogenic lipoprotein profileM Hanefeld
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|March 6, 2003
STOP-NIDDM: a new paradigm for diabetes prevention?M Hanefeld
Zeitschrift Fur Arztliche Fortbildung|January 1, 1984
[Nutrition in hyperlipoproteinemias from the preventive and therapeutic viewpoint]M Hanefeld
Pageof 23